scholarly journals Comparison between botulinum toxin and steroid septal injection in the treatment of allergic rhinitis

2022 ◽  
Author(s):  
Cheng‐Chieh Huang ◽  
Kuan‐Wei Chen ◽  
Chih‐Wen Twu ◽  
Hung‐Meng Huang ◽  
Hsin‐Chien Hsu
Keyword(s):  
Allergic Rhinitis ◽  
Botulinum Toxin

Evaluation of the effect of intranasal infiltrated botulinum toxin-A on a model of allergic rhinitis in rabbits: An Experimental Study

2016 ◽  
Vol 83 ◽  
pp. 51-56 ◽  
Author(s):  
Murat Salih Güneş ◽  
Ismail Külahlı ◽  
Kerem Kökoğlu ◽  
Alperen Vural ◽  
Deniz Avcı ◽  
...  
Keyword(s):  
Experimental Study ◽  
Allergic Rhinitis ◽  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Toxin A

Treatment of allergic rhinitis with intranasal infusion of botulinum toxin type A in mice

Life Sciences ◽  
2016 ◽  
Vol 147 ◽  
pp. 132-136 ◽  
Author(s):  
Kunihide Aoishi ◽  
Hirotaka Takahashi ◽  
Naohito Hato ◽  
Kiyofumi Gyo ◽  
Makoto Yokota ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type

scholarly journals Comparing the Effects of Botulinum Toxin-A and Cetirizine on the Treatment of Allergic Rhinitis

2013 ◽  
Vol 62 (2) ◽  
pp. 245-249 ◽  
Author(s):  
Sayyed Mostafa Hashemi ◽  
Ahmadreza Okhovat ◽  
Saghi Amini ◽  
Mahdi Pourghasemian
Keyword(s):  
Allergic Rhinitis ◽  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Toxin A

scholarly journals The Effect of Combined Septal and Turbinate Injection of Botulinum Toxin Type A in Allergic Rhinitis

2020 ◽  
Author(s):  
Mostafa Ismail ◽  
Alaa Nabil ◽  
Mostafa Nasr ◽  
balegh abdel hak ◽  
Osama Awad ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Botulinum Toxin ◽  
Nasal Congestion ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Limited Effectiveness ◽  
Significant Difference ◽  
Before And After

Objectives: Allergic rhinitis ( AR) has been recently increasing in prevalence, and traditional treatment strategies sometimes show limited effectiveness for patients with intractable AR. Botulinum toxin type A (BTX-A) is among the increasingly used alternative treatment options. This study was conducted aiming at clinical assessment of the effect of combined septal and turbinate injection of BTX-A for management of uncontrolled AR. Design and setting: A single-arm pilot study enrolled 40 patients having moderate to severe uncontrolled AR were recruited in between October 2018 and August 2019. Each patient received 45 units of BTX-A injected in 3 fixed points of each side of the nose: inferior turbinate (15IU), middle turbinate (15IU) and nasal septum (15IU). All patients were evaluated in terms of nasal hypersecretions, congestion and sneezing with visual analogue scale prior to treatment and at weeks 1, 2, 4, 8 and 12 during the follow-up period. Results: Throughout the 12 weeks follow-up period, a significant difference in the degree of nasal hypersecretions could be identified before and after BTX-A injection. Sneezing differed significantly only in the first 4 weeks while nasal congestion did not differ significantly, before and after BTX-A injection. BTX-A was well tolerated by the patients, with no serious adverse or systemic effects. Conclusion: Combined septal and turbinate injection of BTX-A, in patients with uncontrolled AR, may be a long-lasting therapeutic option for the treatment of nasal hypersecretions, but not as effective as for sneezing and nasal congestion.

Sequential degranulation of eosinophils induced by antigen or autocoids in allergic humans

1986 ◽  
Vol 44 ◽  
pp. 354-355
Author(s):  
Kate W. Sjoerdsma ◽  
W. James Metzger
Keyword(s):  
Allergic Rhinitis ◽  
Bronchoalveolar Lavage ◽  
Allergic Asthma ◽  
Skin Test ◽  
Positive Skin Test ◽  
Positive Skin ◽  
Human Eosinophil ◽  
Asthmatic Patients ◽  
Allergic Asthmatic ◽  
History Of

Eosinophils are important to the pathogenesis of allergic asthma, and are increased in bronchoalveolar lavage within four hours after bronchoprovocation of allergic asthmatic patients, and remain significantly increased up to 24 hours later. While the components of human eosinophil granules have been recently isolated and purified, the mechanisms of degranulation have yet to be elucidated.We obtained blood from two volunteers who had a history of allergic rhinitis and asthma and a positive skin test (5x5mm wheal) to Alternaria and Ragweed. Eosinophils were obtained using a modification of the method described by Roberts and Gallin.

Effects of Selected Rhinologic Disorders on the Perception of Nasal Resonance in Children

1984 ◽  
Vol 15 (1) ◽  
pp. 44-50 ◽  
Author(s):  
Michael P. Rastatter ◽  
Melvin Hyman
Keyword(s):  
Allergic Rhinitis ◽  
Clinical Implications ◽  
Normal Children ◽  
Nasal Resonance

A group of sophisticated listeners judged the nasal resonance characteristics of normal children versus children evidencing selected rhinologic disorders under three speaking conditions. Results showed that perceptions of denasality are influenced by both speakers and speaking tasks. That is, children with allergic rhinitis and edemic adenoids were perceived as being denasal when they produced VCV utterances and recited sentences. However, their resonance characteristics were deemed normal for vowel productions. Interestingly, children with severely deviated septums were judged to have normal nasal resonance under all speaking conditions. Clinical implications are discussed.

Severe Drooling and Treatment With Botulinum Toxin

2012 ◽  
Vol 21 (1) ◽  
pp. 15-21
Author(s):  
Merete Bakke ◽  
Allan Bardow ◽  
Eigild Møller
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Health Risk ◽  
Flow Rate ◽  
Clinical Evidence ◽  
Acetylcholine Release ◽  
Psychosocial Problems ◽  
Rate Reduction ◽  
Local Inhibition ◽  
Surgical Treatments

Severe drooling is associated with discomfort and psychosocial problems and may constitute a health risk. A variety of different surgical and non-surgical treatments have been used to diminish drooling, some of them with little or uncertain effect and others more effective but irreversible or with side effects. Based on clinical evidence, injection with botulinum toxin (BTX) into the parotid and submandibular glands is a useful treatment option, because it is local, reversible, and with few side effects, although it has to be repeated. The mechanism of BTX is a local inhibition of acetylcholine release, which diminishes receptor-coupled secretion and results in a flow rate reduction of 25–50% for 2–7 months.

Sign in / Sign up

Export Citation Format

Share Document